Nplate (Romiplostim) Neutralizing Antibody, Mouse Monoclonal (Clone 5D5-G2) [MA201N-100 or MA201N-025] 

Nplate (Romiplostim) is a thrombopoietin receptor (TPO-R) agonist marketed by Amgen for the treatment of thrombocytopenia (Reference 1, see below). It has been approved for the treatment of both adult and pediatric patients with immune thrombocytopenia (ITP), a condition that occurs when the blood platelet count is too low. Nplate (Romiplostim) is a recombinant human IgG Fc fusion protein produced in E. coli (2).

GenHunter has 2 neutralizing monoclonal antibodies against Nplate (Romiplostim): Clone 5D5-G2 and Clone 2A3-B6. These NAbs have specificity against TPO-R Mimetic Peptide (Nplate).

Nplate (Romiplostim) Neutralizing Antibody Determination: Nplate neutralizing antibody assay for the two mAbs was carried out with Ba/F3 (c-Mpl) cell bioassay method in which Ba/F3 (c-Mpl) cells were grown in the presence of Nplate with or without the mAbs. EC50 (see data in specifications tab below) was determined at the concentration where a mAb caused 50% inhibition of the cell proliferation.

Nplate (Romiplostim) Antibody Products Available:

We also have many other antibody and antigen products (CLICK HERE or names below) including for:
SARS-CoV-2 (COVID-19), Human IL-24, Human IL-20R2, Nplate (Romiplostim), Human VEGF-R, Endo180 (uPARAP, CD280), Tumor Necrosis Factor (TNF) superfamily, SIRPα (Signal-regulatory protein alpha), Rabies virus, Trimer-Tag, RSV (Respiratory Syncytial Virus), HSV-2 (Herpes Simplex Virus 2), and AP (alkaline phosphatase).

References:

1. Kuter, D.J. et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. (2008) The Lancet. 371:395-403. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60203-2/abstract
2. Cines, D.B. et al: Romiplostim. (2008) Nature Reviews Drug Discovery. 7:887-888. https://www.nature.com/articles/nrd2741

All products are FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.